Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Hospital

Distinct Healthcare IPO Hong Kong: Private Provider Seeks $36M HKEX Listing

Fineline Cube Jan 29, 2026
Company Deals

Biogen’s Litifilimab Secures FDA Breakthrough Therapy Designation for Lupus

Fineline Cube Jan 29, 2026
Company Deals

Seamless Therapeutics Partners with Eli Lilly on $1.12B Hearing Loss Recombinase Deal

Fineline Cube Jan 29, 2026
Company Deals

Apeloa Partners with MindRank on AI Drug Development Platform

Fineline Cube Jan 28, 2026
Company Deals Medical Device

IVD Medical Launches Nipah Virus Detection Kit with AI Early Warning Platform

Fineline Cube Jan 28, 2026
Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link

Fineline Cube Jan 28, 2026
Company Drug

Changchun High‑Tech’s Firsekibart Filing Accepted for Non‑Infectious Uveitis

Fineline Cube Jan 29, 2026
Company Drug

Sino Biopharm’s TQA3605 Meets Endpoint in Hepatitis B Phase II Trial

Fineline Cube Jan 28, 2026
Company Drug

Huadong Medicine Gets NMPA Green Light for Sirolimus Real-World Study in Pediatric Epilepsy

Fineline Cube Dec 6, 2023

Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has received approval from the...

Company Drug

Sino Biopharmaceutical Initiates Phase I Trial for Hepatitis B siRNA Drug TQA3038

Fineline Cube Dec 6, 2023

Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced the...

Company Drug

Jingxin Pharmaceutical’s Didaxini Gains NMPA Approval as Category 1 Drug

Fineline Cube Dec 6, 2023

Jingxin Pharmaceutical Co., Ltd (SHE: 002020), a Chinese pharmaceutical company, has announced that it has...

Company Drug

Biocytogen Pharmaceuticals Secures US Patent for Fully Human Antibody Mice Platform RenMab

Fineline Cube Dec 6, 2023

Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a China-based Contract Research Organization (CRO), has announced...

Company Drug

China’s Betta Pharmaceuticals Advances CFT8919 for EGFR-Mutated NSCLC After NMPA Approval

Fineline Cube Dec 6, 2023

Betta Pharmaceuticals Co., Ltd (SHE: 300558), a Chinese pharmaceutical company, has announced that it has...

Company Drug

Ascletis Pharma’s Denifanstat Advances to Phase III for Severe Acne Vulgaris Treatment

Fineline Cube Dec 6, 2023

Ascletis Pharma Inc., (HKG: 1672) a China-based biotechnology company, has announced the commencement of a...

Company Medical Device

Sino Medical Secures Market Approval in Taiwan for NC Rockstar Coronary Catheter

Fineline Cube Dec 6, 2023

Sino Medical Sciences Technology Inc. (SHA: 688108) has announced that its NC Rockstar non-compliant coronary...

Company Drug

Luye Pharma’s Lurbinectedin for Metastatic SCLC Wins Macau Regulatory Nod

Fineline Cube Dec 5, 2023

Luye Pharma Group (HKG: 2186), a Chinese pharmaceutical company, has announced that Macau’s medical products...

Company Drug

Yantai Dongcheng Pharmaceutical Gets NMPA Green Light for FAP-Targeting Radiotherapeutic Drug

Fineline Cube Dec 5, 2023

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has received approval...

Company Drug

Tonghua Dongbao Pharmaceuticals Secures NMPA Approval for Biosimilar Liraglutide

Fineline Cube Dec 5, 2023

Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has announced that it has received...

Company Drug

Simcere Pharmaceutical’s SIM0501 Receives FDA Approval for Advanced Solid Tumor Clinical Trial

Fineline Cube Dec 5, 2023

Simcere Pharmaceutical Group (HKG: 2096) has announced that it has received clinical trial approval from...

Company

WuXi Biologics Shares Plunge 22% on Slower CDMO Industry Growth and Revenue Shortfall

Fineline Cube Dec 5, 2023

WuXi Biologics (HKG: 2269) experienced a 22% decline in its share price on Monday, December...

Company Deals

Abbisko Therapeutics Strikes Licensing Deal with Merck KGaA for CSF-1R Inhibitor Pimicotinib

Fineline Cube Dec 5, 2023

Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has announced a licensing agreement...

Company Deals

Boehringer Ingelheim Partners with Shanghai Handu Pharma to Enhance Oral Medication Delivery

Fineline Cube Dec 5, 2023

Boehringer Ingelheim (BI), a German pharmaceutical company, has entered into a partnership with Shanghai Handu...

Company Deals

Gedeon Richter Acquires Rights to Mithra’s Contraceptive and Menopause Treatments for Chinese Market

Fineline Cube Dec 5, 2023

Gedeon Richter Plc, a Hungarian pharmaceutical company, and Belgium’s Mithra (OTCMKTS: MITPF) have entered into...

Company Deals

Aspen Pharmacare Holdings to Boost China Presence with Full Acquisition of Sandoz’s Subsidiary

Fineline Cube Dec 5, 2023

Aspen Pharmacare Holdings (JSE: APN), a South Africa-based pharmaceutical company, is poised to enhance its...

Company Drug

AstraZeneca Halts Late-Stage Trials for Lokelma in Hyperkalemia Due to Timing and Event Rate Issues

Fineline Cube Dec 5, 2023

AstraZeneca (AZ; NASDAQ: AZN), a leading UK pharmaceutical company, has announced the termination of two...

Company Deals

Roche Expands Beyond Oncology with USD 2.7 Billion Carmot Therapeutics Acquisition

Fineline Cube Dec 5, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has entered into an agreement to acquire U.S. biotech...

Company Drug

Stem-Cell Startup Xellsmart Earns FDA Orphan Drug Designation for ALS Therapy

Fineline Cube Dec 5, 2023

Xellsmart, a stem-cell startup headquartered in Suzhou, has announced that it has received orphan drug...

Company Drug

Worg Pharmaceuticals Gets FDA Approval for Phase II Graves’ Disease Study

Fineline Cube Dec 5, 2023

Worg Pharmaceuticals, a Hangzhou-based developer of allergic drugs, has received the green light from the...

Posts pagination

1 … 383 384 385 … 615

Recent updates

  • Servier Oncology Revenue Drives 16% Growth, US Sales Surge 70%
  • Changchun High‑Tech’s Firsekibart Filing Accepted for Non‑Infectious Uveitis
  • Danaher Q4 Revenue Grows 3% to $24.6B on Biotech and Diagnostics Innovation
  • Distinct Healthcare IPO Hong Kong: Private Provider Seeks $36M HKEX Listing
  • Merck Establishes Chongqing China Branch in Milestone Expansion
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Servier Oncology Revenue Drives 16% Growth, US Sales Surge 70%

Company Drug

Changchun High‑Tech’s Firsekibart Filing Accepted for Non‑Infectious Uveitis

Company

Danaher Q4 Revenue Grows 3% to $24.6B on Biotech and Diagnostics Innovation

Company Deals Hospital

Distinct Healthcare IPO Hong Kong: Private Provider Seeks $36M HKEX Listing

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.